Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies

被引:9
|
作者
Chan, WY
Levi, R
Wo, NC
Koyama, M
Stoev, S
Cheng, LL
Manning, M
机构
[1] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA
[2] Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA
关键词
vasopressin peptide; selective hypotensive; vasopressin receptor; vasodilating; vasopressin receptor subtype; new; structure-activity-relationship;
D O I
10.1016/S0014-2999(01)00959-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recently, we discovered a series of peripheral acting selective hypotensive vasopressin peptides. Whether these peptides may interact with receptors outside the vasopressin receptor family and affect cardiac function could not be excluded. Accordingly, we tested the effects of these hypotensive vasopressin peptides on blood pressure and heart rate in intact rats and on the heart rate, ventricular contractile force and coronary flow of isolated perfused rat hearts. We found that the hypotensive vasopressin peptides did not modify cardiac function, either in vivo or in vitro. The vasodepressor potency was reduced when assayed in rats with vasopressin-maintained baseline blood pressure, suggesting that vasopressin and the hypotensive peptide compete for a common vasodilating vasopressin receptor in the vasculature. We have now synthesized more potent and radioiodinatable hypotensive peptides that could serve as lead compounds for the development of a radiomarker for the putative vasodilating vasopressin receptor. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 50 条
  • [1] Truncated Orexin Peptides: Structure-Activity Relationship Studies
    German, Nadezhda A.
    Decker, Ann M.
    Gilmour, Brian P.
    Thomas, Brian F.
    Zhang, Yanan
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (12): : 1224 - 1227
  • [2] Development of plasmin-selective inhibitors and studies of their structure-activity relationship
    Okada, Y
    Matsumoto, Y
    Tsuda, Y
    Tada, M
    Wanaka, K
    Hijikata-Okunomiya, A
    Okamoto, S
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2000, 48 (02) : 184 - 193
  • [3] Structure-activity relationship of rubiscolins as δ opioid peptides
    Yang, SZ
    Sonoda, S
    Chen, LP
    Yoshikawa, M
    PEPTIDES, 2003, 24 (04) : 503 - 508
  • [4] Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors
    Gewald, Rainer
    Rueger, Carla
    Grunwald, Christian
    Egerland, Ute
    Hoefgen, Norbert
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (22) : 6652 - 6656
  • [5] Discovery of a Novel FGFR4 Selective Inhibitor via Structure-Activity Relationship Studies of FGF401
    Sun, Chang'an
    Fang, Lei
    Gou, Shaohua
    CHINESE JOURNAL OF ORGANIC CHEMISTRY, 2020, 40 (01) : 84 - 94
  • [6] Synthesis and structure activity relationship studies of novel Staphylococcus aureus Sortase A inhibitors
    Chenna, Bala Chandra
    King, Jason R.
    Shinkre, Bidhan A.
    Glover, Amanda L.
    Lucius, Aaron L.
    Velu, Sadanandan E.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (09) : 3752 - 3761
  • [7] Research Progress in Structure-Activity Relationship of Bioactive Peptides
    Li, Ying
    Yu, Jianmei
    JOURNAL OF MEDICINAL FOOD, 2015, 18 (02) : 147 - 156
  • [8] Structure-activity relationship study: short antimicrobial peptides
    Oh, JE
    Hong, SY
    Lee, KH
    JOURNAL OF PEPTIDE RESEARCH, 1999, 53 (01): : 41 - 46
  • [9] Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship
    Okada, Y
    Tsuda, Y
    Tada, M
    Wanaka, K
    Okamoto, U
    Hijikata-Okunomiya, A
    Okamoto, S
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2000, 48 (12) : 1964 - 1972
  • [10] Structure-Activity-Relationship Study of the Novel p21/waf1 Inhibitor for Anti-Cancer Agents against Renal Cell Carcinoma
    Park, See-Hyoung
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2015, 11 (04) : 387 - 393